
Geovax Labs (GOVX) Stock Forecast & Price Target
Geovax Labs (GOVX) Analyst Ratings
Bulls say
Geovax Labs is strategically focused on advancing its GEO-MVA vaccine candidate, supported by regulatory alignment and completion of clinical supply manufacturing, placing the company in a potentially accelerated path to late-stage development of orthopoxvirus vaccines. The company's balance sheet is the key limiting factor and likely to remain a focus until additional capital or strategic support is secured. Despite this, the company plans to have a pivotal execution year in 2026 with multiple clinical readouts, including for GEO-CM04S1 and Gedeptin, positioning it for potential late-stage catalysts.
Bears say
Geovax Labs is currently facing challenges in its pipeline, with GEO-MVA being the primary focus despite facing delays in data results and a planned immunobridging study in 2026. The company's decision to implement a 1-for-10 reverse stock split in 2023 could signal previous weaknesses and result in heightened dilution risks for potential future capital raises, causing investor sensitivity. Additionally, while the company has multiple programs approaching value-inflection points, including Gedeptin's combination study in head and neck cancer and GEO-CM04S1's Phase 2 data in COVID-19, these are unlikely to have a significant impact on valuation in the near term. Furthermore, the company's ability to manufacture its products may be hindered by historical supply constraints.
This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.
Geovax Labs (GOVX) Analyst Forecast & Price Prediction
Start investing in Geovax Labs (GOVX)
Order type
Buy in
Order amount
Est. shares
0 shares